Abstract This study intended to determine whether the replacement of vitamin D3 with alfacalcidol results in any bone mineral density (BMD) increase in 76 patients unresponsive to the combination of alendronate and conventional vitamin D3 treatment. In these patients the conventional vitamin D3 had been replaced with alfacalcidol (0.5 g/day), and then the patients were followed up for a year. After treatment for 1 year, Wilcoxon test revealed a small but statistically signiWcant (P < 0.001) increase in the BMD values of the forearm and lumbar vertebrae, in the serum calcium and urinary calcium/creatinine ratio in Wrstvoided morning urine. However, the serum alkaline phosphatase activity, phosphorus, parathormone, osteocalcin levels and the urinary D-pyr/creatinine ratio decreased signiWcantly (P < 0.001). As suggested by our results, combination therapy with alendronate and alfacalcidol increases bone density and improves the biochemical markers of bone turnover, without any substantial increase in the incidence of adverse eVects.
Introduction
Osteoporosis is a disorder that leads to enhanced bone fragility through a decrease in the mass as well as deterioration of the microarchitecture of bones. Owing to its high prevalence and negative impact on the quality of life, osteoporosis is the third most important public health disorder (after malignancies and cardiovascular disease), aZicting 200 million people worldwide [1] . Oral bisphosphonates are routinely prescribed for treatment for patients with osteoporosis. Adequate calcium and vitamin D suYciency of the body is essential for antiresorptive treatment to be eVective. According to Horváth et al., serum 25-hydroxyvitamin D 3 level is lower than normal in 40% of elderly nursing home residents, whereas data from Bhattoa et al. reXect the same in 56.7% of postmenopausal women [2, 3] . Some studies demonstrated statistically signiWcant reduction of fractures during 5 years of high dose (100,000 E every 4 months) treatment with vitamin D 3 [4] , but others did not [5] [6] [7] . According to a recent study, in 8-25% of osteoporotic patients, bone loss continues despite adequate treatment with bisphosphonates, administered in combination calcium and vitamin D 3 supplementation [8] . A proportion of these patients may have functional hypovitaminosis D potentially resulting from insuYcient intake (despite supplementation), impaired activation, genuine resistance to vitamin D3 or secondary hyperparathyroidism [9] . In the remainder, the cause underlying the lack of bisphosphonate eVects is unknown.
In osteoporosis, genuine resistance to bisphosphonates is probably non-existent or may be considered extremely uncommon at the least. In Paget's disease, by contrast, where therapy is aimed at achieving complete biochemical remission, resistance to bisphosphonates has been demonstrated by several researchers. The lack of a complete biochemical remission is regarded by some as the criterion for bisphosphonate resistance [10] , whereas according to others [11] , the latter is established by a lower than 50% decrease in serum alkaline phosphatase (AP) level. Notwithstanding the criteria, the prevalence of resistance varies with diVerent bisphosphonates in the range between 83% (etidronate [10] ) and 11% (zolendronate [12] ).
According to additional, relevant evidence, the eYcacy of activated analogues of vitamin D (alfacalcidol, calcitriol) in reducing bone fractures and increasing bone density is superior to that of native vitamin D. This has been demonstrated by several studies in various disease forms, i.e. in postmenopausal osteoporosis, as well as in osteoporosis related to inXammatory joint disease, or glucocorticoid therapy [13] [14] [15] [16] .
This study was intended to ascertain:
1. whether replacing vitamin D 3 with alfacalcidol is followed by an increase in BMD (i.e. bisphosphonate resistance can be overcome) in patients not responding to treatment with a bisphosphonate administered in combination with supplemental calcium and conventional vitamin D 3 ; 2. the incidence of hypovitaminosis D 3 in the study population; 3. the changes occurring in biochemical markers of bone turnover during 1 year of treatment with alfacalcidol; 4. the frequency of adverse events associated with the use of alfacalcidol. 2 at baseline and four patients had GFR lower than 60 ml/min per 1.73 m 2 at starting of the study, two of them had elevated serum PTH levels. In the included patients, the average administered dose of D3 vitamin was 530 U/day along with 1,000 mg of calcium supplementation before the starting of the study.
Patients and methods

Patients
Study design
During the follow-up period of 1 year on average, control visits were scheduled at baseline and at 3-month intervals thereafter. At baseline, a detailed history (concomitant diseases, fractures, osteoporosis and risk factors) was recorded along with appraisal of clinical status by obtaining a lateral X-ray of the lumbosacral spine and performing a laboratory screen [ESR, CRP, CBC, serum calcium, phosphorus, BUN, creatinine, GOT, GPT, AP, albumin, osteocalcin, 25-hydroxyvitamin-D 3 , parathormone (PTH) levels, urinary calcium/creatinine (UCa/Cr) and deoxypyridinoline crosslinks/creatinine (D-pyr/creatinine) ratios]. Bone density was measured in both peripheral bones (DTX200) and in the axial skeleton (DEXA, Lunar DPX Pro) and BMD values obtained from the radius distal segment, as well as the means of the values measured in the Wrst through fourth lumbar vertebrae were taken into account. Serum calcium level and urinary calcium/creatinine ratio were determined at control visits repeated at 3-month intervals. After 1 year, information was gathered on the fractures and renal calculosis that had occurred during the follow-up period, as well as osteodensitometry, lumbosacral X-ray, and laboratory screen were repeated.
Treatment protocol
The pre-existing regimen of alendronate 70 mg once per week was left unchanged, but conventional vitamin D 3 and calcium treatment was replaced with 0.5 g/day alfacalcidol (1 -hydroxvitamin D 3 ). The calcium supplementation was also stopped.
Endpoints
The primary endpoint of the study was deWned as the change measurable (by DEXA) in bone mineral density (BMD) of the forearm and of axial bones 1 year after the introduction of alfacalcidol treatment. Secondary endpoints included changes in clinical chemistry parameters (serum calcium, phosphorus, and alkaline phosphatase levels), biochemical markers of bone turnover (serum osteocalcin, PTH, urinary D-pyr/creatinine), UCa/Cr ratio determined in Wrst-voided morning urine, treatment-emergent adverse reactions, and osteoporotic fractures that occur during follow-up.
Statistical analysis
The diVerences between the values of study parameters (BMD; serum Ca, P, AP, osteocalcin, PTH levels; urinary D-pyr/creatinine and UCa/Cr ratios) determined at two time points were analysed using the SPSS 15.0 software package. First, the normality of diVerences was checked with the Kolmogorov-Smirnov test [normal distribution would allow performing a parametric (t or d) test]. The diVerences between the paired values of all nine variables were signiWcantly diVerent from the normal distribution (P < 0.01 for UCa/Cr and P < 0.001 for the rest). As the data were unsuitable for analysis with the t test, non-parametric Wilcoxon signed rank test was performed to check the uniformity of repeated measurements. (This method is a non-parametric alternative to performing a paired t test.)
Results
Changes in BMD during follow-up
The median of changes as well as the minimal and maximal changes are summarised in Table 1 Compared to baseline values, densitometry results (both BMD values and T scores) obtained after 1-year treatment revealed statistically signiWcant improvement in both regions (Wilcoxon's signed rank test, P < 0.001). increased by 0.1 (median). All these changes were signiWcant (Wilcoxon's signed rank test, P < 0.001) (see Fig. 2 ). The decline of serum alkaline phosphatase level over the follow-up period by a median of 13 U/l was also signiWcant, but clinically not relevant (see Fig. 3 ).
Changes in biochemical markers of bone turnover
Changes in serum parathormone (PTH) level were as expected. At baseline, elevated PTH was ascertained in 32 patients; this number decreased to 16 during the 1-year follow-up. The median change in serum PTH level was signiWcantly lower 1 year later (median change, 10.7 pg/ml) (Fig. 3) . Serum osteocalcin level decreased by 0.4 ng/ml (median) after treatment; this was accompanied by a decrease in the D-pyr/creatinine ratio by 0.2 nmol/mmol (P < 0.001) (Fig. 3) . Although the changes showed high scatter, they proved to be highly signiWcant (Wilcoxon's signed rank test, P < 0.001). The ranges of relative changes expressed as percentages of the base values for all parameters (Fig. 4) .
Adverse events Mild hypercalcaemia (serum calcium level <3 mmol/l) was observed in three patients; no other clinically relevant adverse reactions were seen. There was no signiWcant increase in urinary calcium based on alendronate therapy.
New fractures
As stated above, ten patients had a history of at least one prevalent vertebral or low-trauma peripheral fracture at starting of the study. Four new vertebral and two peripheral Fig. 2 Changes of serum calcium and phosphorus levels, as well as of UCa/creatinine ratio during the study Fig. 3 The change of serum alkaline phosphatase activity (U/l), parathormone level (pg/ml), osteocalcin level (ng/ml) and of urinary deoxypirydinoline crosslinks/ creatinine (D-pyr/creatinine, nmol/mmol) by the end of the follow-up (wrist) fractures were recorded during follow-up. Two of the vertebral fractures were sustained by patients with a prevalent vertebral fracture.
Discussion
Some data from the literature suggest that activated vitamin D derivatives (alfacalcidol, calcitriol), also called D-hormone analogues, are superior to conventional vitamin D, as regards the mitigation of fracture risk. In their meta-analysis of 33 clinical studies, Richy et al. found a 13.4% (delta RD, 95% CI 7.7-19.8) reduction of fracture risk during the use of activated vitamin D 3 derivatives, compared to a mere 6% (delta RDi, 95% CI 1-12) accomplished by treatment with conventional vitamin D3 [13] . The rate diVerence (RD) was statistically signiWcant (ANOVA-1; P < 0.001) Ringe et al. studied the changes of BMD and bone fractures in patients with glucocorticoid-induced osteoporosis, over 3 years of treatment with either alfacalcidol or vitamin D 3 ; both administered with calcium supplementation of 500 mg daily. Changes in the BMD of the lumbar spine were 2.4 versus ¡0.8% (P < 0.0001), and of the femoral neck 1.2 versus 0.8% (P < 0.006), respectively. The proportion of patients who have sustained at least one new vertebral fracture was 9.7% in the alfacalcidol and 24.8% in the control group (risk reduction: 0.61, P = 0.005), whereas the proportions of patients with at least one new non-vertebral fracture were 15 versus 25% (risk reduction: 0.41, P = 0.08).
Taking the occurrence of any type of incident fractures into account, the above proportions were 19.4 versus 40.6%, respectively (risk reduction: 0.52, P < 0.001) [14] . During the AAC study published in 2007, 30-30 patients were randomised into either of the following 3 treatment arms: (a) alfacalcidol 1 g + calcium 500 mg/day; (b) alendronate 70 mg/week + calcium 1,000 mg/day + vitamin D 3 1,000 IU/day; (c) alendronate 70 mg/week + calcium 500 mg/day + alfacalcidol 1 g/day. During the 2 years of follow-up, bone density of the lumbar spine and of the total hip increased by 3%/1.5%, 5.4%/2.4%, and 9.6%/3.8%, respectively. The magnitude of changes observed in patients treated with alendronate + alfacalcidol + calcium was signiWcantly greater than of those seen in the other two groups (P < 0.0001 for lumbar BMD and P < 0.0002 for femur BMD). The number of new osteoporotic (vertebral + nonvertebral) fractures occurring over 2 years of treatment in the three treatment groups was 9, 10, and 2, respectively; this Wnding is also in support of the favourable eVect of alfacalcidol and especially of the combination of alendronate + alfacalcidol on fracture prevention [16] .
As suggested by several studies, administering antiresorptive agents (e.g. bisphosphonates) with activated vitamin D 3 derivatives may increase the success of therapy. The beneWcial eVects of alfacalcidol on intestinal calcium absorption, osteoid mineralization, muscle function and motor coordination, serum PTH level, and the risk of falls may substantially enhance the eYcacy of treatment with bisphosphonates [17, 18] .
The anabolic eVect of alfacalcidol on bone is supported also by in vivo and in vitro data. Under the eVect of alfacalcidol, osteoblasts have been shown to release various growth factors [TGF-, IGF-1 and -2, bone morphogenetic proteins (BMPs), bone matrix proteins (collagen I, osteocalcin, osteopontin)] and thereby counterbalance the reduction of bone turnover during treatment with bisphosphonates [18] [19] [20] [21] . This osteoanabolic eVect of alfacalcidol administered in combination with alendronate has been demonstrated by several studies [21] [22] [23] [24] .
Our study was conducted on patients whose bone density was declining despite adequate treatment with a bisphosphonate and supplementation of calcium plus conventional vitamin D 3 since a year at least. Patients with renal impairment or secondary osteoporosis were not allowed to participate in the study. Notwithstanding this, the study population included a substantial number of patients with decreased serum 25-hydroxyvitamin D 3 levels (n = 38), accompanied by higher than normal serum PTH level (n = 23). This might suggest a potential relationship between resistance to bisphosphonates and the level of vitamin D 3 insuYciency and the increase of serum PTH. Persistence of secondary hyperparathyroidism reduces BMD response to alendronate in older women with osteoporosis [9] . The improvement of the biochemical markers of bone turnover and increasing BMD indicate that patients apparently resistant to treatment with a bisphosphonate plus supplementation with calcium and conventional vitamin D 3 are more likely to beneWt from combination therapy with a Fig. 4 The ranges of relative changes expressed as percentages of the base values for all parameters bisphosphonate and alfacalcidol [9] . The enhanced eYcacy of alendronate and alfacalcidol in combination is probably related to the synergism between the considerably diVerent modes of action of the two components. In particular, the antiresorptive eVect of alendronate is favourably supplemented by the mitigation of osteoclastogenesis [23, 25] and reduction of serum PTH level, along with the stimulation of osteoblast activity [21] , improvement of bone quality [15, 23] and the microarchitecture of trabecular bone by alfacalcidol [23] , which also enhances muscle strength and thereby activates the 'mechanostat' function of the skeleton [18] . The whole array of these eVects might explain the outstanding eVect on bones [17, 18, 24] . Further elucidation of these mechanisms would require large-scale studies with fracture endpoints, deWned in addition to monitoring changes in bone density.
Although the lack of a control group may be considered a potential Xaw of this study, the inclusion of untreated patients losing more than 3% of their bone density each year would have been ethically questionable at the least.
Conclusion
As shown by the results of this study, patients whose bone density decreases inexorably despite adequate treatment with alendronate and supplemental calcium and vitamin D 3 might beneWt from a combined treatment of alendronate with alfacalcidol. The latter combination accomplished signiWcant increase of BMD along with improvement of the biochemical markers of bone turnover, but without any substantial increase in the incidence of adverse eVects.
